Long-acting Octreotide, Not Beneficial to Liver Cancer Patients
According to the results of a new double blind study published in the January 2007 issue of Hepatology (the official journal of the American Association for the Study of Liver Diseases (AASLD)), long-acting octreotide does not improve outcomes for patients with liver cancer as compared to placebo.
Also known as hepatocellular carcinoma (HCC), liver cancer is a common malignancy with very few treatment options.
Liver transplant or resection can potentially cure the condition, but most patients are inoperable once they are diagnosed.
In search for more minimally invasive treatments, previous studies suggested that short-acting octreotide could improve survival for patients with HCC while its twice-daily administration was associated with many side effects.
In this new study, the long-acting octreotide was put to test with negative results.
“This is the first randomized-controlled trial that analyzed the effect of long-acting octreotide on HCC growth and patient survival. We observed no survival improvement in HCC patients treated with octreotide in contrast to placebo treated patients.”
Source: Science Daily
[Photo Credit: Bedford Labs]
Tags: liver-cancer, octreotideRelated Stories
POSTED IN: on anti-cancer ingredients, on liver cancer
0 opinions for Long-acting Octreotide, Not Beneficial to Liver Cancer Patients
No one has left a comment yet. You know what this means, right? You could be first!
Have an opinion? Leave a comment: